

POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM

**CRITICAL PATH INSTITUTE** 

## AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE EXTERNALLY-LED PATIENT FOCUSED DRUG DEVELOPMENT MEETING

## JOIN US AS A SPONSOR! Virtual event, August 29, 2023

Are you ready to seize a unique opportunity to be recognized as a supporter for finding new treatments for ARPKD? Join the PKD Foundation and the Critical Path Institute's Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a sponsor for the upcoming Externally-Led Patient Focused Drug Development Meeting (EL-PFDD) for Autosomal Recessive Polycystic Kidney Disease (ARPKD) on August 29, 2023.

Externally led patient-focused drug development (EL-PFDD) meetings bring together

patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, physicians, and researchers who are experts in a particular disease. The goal of this meeting is to hear directly from patients, their families, caregivers, and patient advocates about what it's like to live with ARPKD, so the FDA and pharmaceutical companies can better understand the patient experience. This patient input can help the FDA make informed decisions on approvals of potential therapies for ARPKD, and pharmaceutical companies to develop medicines and clinical trials that are meaningful for patients.

### **Sponsorship Levels and Details**

We are seeking sponsorship to ensure that patients' experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation. The funds will be used to cover the cost of hosting the EL-PFDD meeting and developing a Voice of the Patient post-meeting report. Sponsorships and associated benefits will be based upon the level of contribution: Impact Champion, Innovation Champion, and Inspiration Champion.

IMPACT CHAMPION Exclusive Opportunities for Sponsorship of \$20,000

#### Benefits include:

- Most prominent sponsor logo on meeting webpage and registration site
- Most prominent logo placement on meeting emails to prospective and confirmed attendees
- ✓ Verbal recognition, with logo, on thank you slide displayed at the start of meeting
- 𝞯 Verbal recognition, with logo, on thank you slide displayed during meeting breaks
- ✓ Logo placement in post-meeting Voice of the Patient Report

#### **INNOVATION CHAMPION** Exclusive Opportunities for Sponsorship of \$10,000

#### Benefits include:

- Sponsor logo on meeting webpage and registration site
- ✓ Logo placement on meeting emails to prospective and confirmed attendees
- ✓ Verbal recognition, with logo, on thank you slide displayed during meeting breaks
- ✓ Logo placement in post-meeting Voice of the Patient Report
- ✓ Early access to post-meeting Voice of the Patient Report

#### Benefits include:

- Sponsor logo on meeting webpage and registration site
- ✓ Logo placement on meeting emails to prospective and confirmed attendees
- Solution Verbal recognition, with logo, on thank you slide displayed at the start of meeting
- 𝞯 Verbal recognition, with logo, on thank you slide displayed during meeting breaks
- ✓ Recognition, with logo, on C-Path and PKD Foundation social media channels
- Solution Content State And Content State And

#### To secure your sponsorship opportunity, please contact Krystn Kuckelman, KrystnK@pkdcure.org

#### About the PKD Foundation

The PKD Foundation is the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD). We fund research, education, advocacy, support, and awareness on a national and local level. Since 1982, we have proudly funded more than 1,300 research projects and leveraged \$1.5B in research funds, making us the largest private funder of PKD research. We fund basic and clinical research, nephrology fellowships, and scientific meetings with a simple goal: to discover and deliver treatments and a cure for PKD. For more information, visit pkdcure.org.

#### **About Critical Path Institute**

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Amsterdam, Netherlands, with additional staff in multiple other locations. For more information, visit **c-path.org** and **c-path.eu**.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling \$17,612,250, and 45% funded by non-government source(s), totaling \$14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit **FDA.gov**.

# CRITICAL PATH

**INSPIRATION CHAMPION** Exclusive Opportunities for Sponsorship of \$5,000